CD8A and neoplasm: Even when combined with alternate immunotherapies, including tumor antigen-specific CD8+ T cell transfer, high-dose DMXAA regimens failed to confer superior therapeutic benefits, owing to contraindicated impact on the recruitment and function of immune cells within the TME [38].